



## **MANDATE, OBJECTIVES AND RULES OF PROCEDURE FOR THE CHMP EFFICACY WORKING PARTY**

### **I. GENERAL CONSIDERATIONS**

According to the CHMP rules of procedure, the CHMP may consult its working parties on any scientific issue related to their specific fields of expertise. The CHMP may also delegate certain tasks associated with the scientific evaluation of applications, or drafting of guidelines to the relevant working parties. The tasks identified by the CHMP should be included in the work programme of each working party to be adopted by the CHMP.

The Efficacy Working Party is therefore established to provide recommendations to the Committee on all matters relating directly or indirectly to the clinical part of drug development and to perform the tasks described under section II.

The EWP was set up in 1995 to facilitate the work of the CHMP in the mentioned area. The purpose was to create a group to hold discussions concerning the clinical part of drug development, harmonise requirements and interpretation of clinical data.

### **II. MANDATE AND OBJECTIVES**

The EWP is established to provide recommendations to the CHMP on all matters relating directly or indirectly to the clinical part of drug development including, but not limited to the tasks defined below:

- Preparation, review and update of guidelines in specific therapeutic areas and on methodology and interpretation of clinical trials (this might include statistical issues, but also consideration of alternative methodology for specific situations, like clinical trials in small populations)
- Support to dossier evaluation.
- At the request of the CHMP, provision of scientific advice on general and product specific matters related to the clinical part of drug development.
- Liaison with interested parties (Learned societies, public health professionals, patients' organisations, pharmaceutical industry representatives) (See V Rules of procedure point 9).
- International cooperation on clinical related matters (interaction with FDA, other regulatory Agencies, and with WHO)
- Liaison and contribution with Scientific Advice Working Party on general and specific matters related to clinical trials

- Liaison with other Working parties or Ad-Hoc expert groups to develop guidance on specific multidisciplinary issues, contributing on the clinical part.
- Advice, through the CHMP, to European Commission on clinical development related issues
- On request, advice, through the CHMP, to MRFG on efficacy related matters
- Where needed and agreed by the CHMP, interaction with the COMP.
- Ensure knowledge of guidelines by discussing concept, major issues and controversies.
- Focus and catalyst for training for clinical assessment, establishing a network of specialised assessors in various therapeutic fields.
- Contribution and organisation of efficacy related workshops and training
- Contribution to ICH efficacy issues
- Ensure EWP/CHMP guidelines are consistent with other CHMP activities.
- Setting up of drafting groups (see VI. Rules of Procedure, point 4)
- Ensure overall consistency between EWP drafting groups.

### **III. COMPOSITION AND RULES OF PARTICIPATION**

The Efficacy Working Party is composed of experts selected from the European experts list according to their specific expertise.

All members of the Committee are invited to nominate 1 expert to be member of the Efficacy Working Party (one member per Member State).

The final composition shall be agreed by CHMP.

Membership of a working party implies a commitment to participate actively in the work of that working party and to attend the meeting of the working party regularly.

A member may nominate a replacement to participate in those exceptional cases where he or she is unable to attend a meeting.

Members who want to bring additional experts should notify the EMEA Secretariat in advance to the meeting, subject to the agreement of the Chairperson.

Meeting documentation will be distributed to an agreed list of recipients drawn up by the EMEA with the agreement of the Chairperson.

Observers from non-EEA countries may participate with the agreement of the Chairperson and the EMEA.

Specific confidentiality rules will apply to observers.

CHMP members are encouraged to take an active role in the activities of the Efficacy Working Party.

### **IV. MEETING FREQUENCY**

The EWP shall meet for a two-day session 4 to 5 times per year in accordance with the adopted Work Programme. The dates of the meetings shall be included in the work programme of the Efficacy Working Party.

EWP Drafting groups will meet for a one-day session 2 to 3 times per year, in the margin of the plenary meeting of the Efficacy Working Party.

## **V. RULES OF PROCEDURE**

### **1. Responsibilities of Chairperson and Vice-Chairperson**

1. The Chairperson, in his absence the Vice-Chairperson, is responsible for the scientific and efficient conduct of the business of the working party and shall in particular:

- Plan the work of the working party together with the EMEA Secretariat;
- Monitor, together with the EMEA Secretariat, that the rules of procedure are respected;
- Ensure that at the beginning of each meeting any potential conflict of interest is declared regarding any particular item to be discussed by the Working Party;
- Aim to achieve consensus on issues discussed by the Working Party
- Decide in exceptional cases, when a vote is necessary;
- Ensure, together with the EMEA Secretariat, the regulatory and scientific consistency of the Efficacy Working Party's recommendations;
- Co-ordinate together with the EMEA secretariat the work of the Efficacy Working Party with that of the other relevant Working Parties of the Agency
- Report on the activities of the Efficacy Working Party to the CHMP or other Working Party as appropriate

2. The Vice-Chairperson will deputise for the Chairperson when the latter is unable to chair either all or part of the working party meeting. On such occasions the Chairperson will seek the agreement of the Vice-Chairperson as early as possible, prior to the meeting and the EMEA Secretariat shall be informed immediately.

### **2. Election of Chairperson and vice Chairperson**

The Chairperson and Vice Chairperson of the Efficacy Working Party shall be elected by the members of the CHMP for a term of the Committee. A Committee member, an alternate or a member of the Efficacy Working Party may be elected by the Committee to fulfil this responsibility. Regardless of the time of election of the Chairperson he/she shall be appointed for the term of the Committee. This appointment may be renewed.

Nominations should be submitted in writing to the EMEA secretariat no later than the start of the Committee meeting at which election of the working party chairperson is to take place.

Candidates shall submit a brief résumé in support of their candidature at the time of the nomination.

The election of the Chairperson and the Vice-Chairperson, where appropriate, shall follow the same procedure as that for the election of the chairperson of Committee as stated in Article 3, paragraphs 1 to 4, of the Rules of Procedure of the CHMP.

### **3. Organisation of meetings and reporting arrangements**

1. The Efficacy Working Party shall meet regularly at the Agency

---

2. The dates of meetings are decided on an annual basis in consultation with the Efficacy Working Party and the CHMP.
3. The meetings will be held and minuted in English.
4. The draft agenda for every meeting shall be circulated, together with the relating documents, by the EMEA Secretariat, in consultation with the chairperson, at least 14 calendar days before the meeting.
5. When a Member of the Efficacy Working Party is unable to participate to a meeting, part of meeting, or discussion topic due to conflict of interest, he/she must inform the Secretariat in advance in writing.
6. The Efficacy Working Party may identify and propose topics for its consideration. Any proposal for a guideline, providing adequate justification, shall be transmitted to the CHMP for endorsement in the form of Concept Paper to be discussed and endorsed by the CHMP.
7. Any recommendation from the Efficacy Working Party shall be transmitted to the Committee for adoption.
8. When considered appropriate by the Efficacy Working Party, oral presentations by companies, expert groups or representatives of professional bodies, can be made during working party meetings on matters directly related to the activities of the working party, following agreement of the Committee.
9. The Efficacy Working Party shall prepare an annual work programme for adoption by the CHMP which shall include topics identified in accordance with point 6 above and any specific tasks identified by the CHMP. The work programme shall be regularly reviewed and updated as necessary with the agreement of the CHMP.
10. Agenda, table of conclusions and minutes of the meetings of the working party should be circulated to the CHMP.
11. The Chairperson will be invited to attend plenary meetings to report on the activities on the Efficacy Working Party and ensure liaison with the work of the CHMP.
12. The mandate of the Efficacy Working Party shall be agreed by the CHMP. It shall be reviewed, at least at the start of each new term of the CHMP.

#### **4. Drafting Groups**

For specific areas, the Efficacy Working Party will convene drafting groups. They will be constituted of members of the working party or experts, as appropriate. Their tasks will be defined in an annex to this mandate.

The drafting group will report to its working party in direct line.

#### **5. Participation of Experts in meetings**

1. When necessary, the Efficacy Working Party may avail itself of the services of experts in specific scientific or technical fields. Such experts shall have proven experience in the assessment of medicinal products or in their field of expertise and be included in the European Experts list. Where appropriate members from patient organisations or health care professionals may act as experts.

2. The names of these experts shall be notified to the EMEA Secretariat before the meeting that they are due to attend.

## **6. Guarantees of independence**

1. The members of the Efficacy Working Party and experts referred to above shall not have any direct interests in the pharmaceutical industry, which could affect their impartiality. They shall undertake to act in the public interest and in an independent manner, and shall make an annual declaration of their financial interests. All indirect interests that could relate to the pharmaceutical industry shall be entered in a register held by the Agency, which is accessible to the public, on request at the Agency's office.

2 Members of the Efficacy Working Party and experts attending these meetings shall declare at the beginning of each meeting any specific interests, which could be considered to be prejudicial to their independence with respect to the points of the agenda. These declarations shall be made available to the public.

3. The specific provisions for handling declaration of interests and confidentiality undertakings as defined in the EMEA Policy on the Handling of Conflicts of Interests for Committee Members and Experts, adopted by the Management Board (EMEA/H/31653) are applicable to members of the Efficacy Working Party and experts participating in their activities.

## **7. Code of conduct**

Members of the Efficacy Working Party and experts participating in the EMEA's activities shall abide by the principles set out in the EMEA Code of Conduct.

## **8. EMEA Secretariat**

1. Under the authority of the Executive Director, the EMEA secretariat shall provide technical, scientific and administrative support to the Efficacy Working Party. This includes the following:

- Provide technical and scientific support to rapporteurs (guidelines), and other members of the Efficacy Working Party
- Provide legal, regulatory and scientific support to the Efficacy Working Party
- Prepare and co-ordinate the work of the Efficacy Working Party in consultation with their Chairperson;
- Organise meetings of the Efficacy Working Party ensuring timely circulation of meeting documents;
- Facilitate the necessary contacts between the Efficacy Working Party and the CHMP
- Ensure adequate co-ordination of the work carried out within the Efficacy Working Party, the CHMP and other concerned working parties and/or scientific advisory groups;
- Contribute to the overall quality assurance and assurance of scientific and regulatory consistency of the documents / recommendations of the Efficacy Working Party in co-operation with the Chairperson or Vice-Chairperson, as appropriate;
- Prepare the agenda, table of conclusions and minutes of the meetings of Efficacy Working Party in consultation with the Chairperson;
- Communicate when necessary any CHMP recommendations relevant to the Efficacy Working Party to interested parties;
- Contribute to the identification of experts

2. The Executive Director of the Agency, members of the EMEA secretariat, and representatives of the Commission, may attend all meetings of the working party.

## **9. Contacts with Interested Parties**

1. Where relevant, the Efficacy Working Party will establish contacts, on an advisory basis, with parties concerned with the use of medicinal products, in particular patient organisations and health-care professionals' associations.

2. Draft guidelines and general regulatory developments will be subject to public consultation of all interested parties (Member States, industry, health care professionals, patients/consumers or other).

3. When considered appropriate by the Efficacy Working Party, oral presentations by interested parties can be made during Efficacy Working Party meetings in earlier stages of development of guidelines. The Efficacy Working Party may also meet with interested parties to discuss general matters or specific scientific issues with the agreement of the CHMP and under specific conditions to be agreed by the CHMP.

4. In any case, the Efficacy Working Party shall neither conduct any deliberations nor reach any formal decisions in the presence of members of interested parties.

5. Before any consultation session, interested party representatives and Efficacy Working Party members will communicate to the EMEA Secretariat the points they would like to be discussed, so that an agenda of the session can be prepared for agreement by the Efficacy Working Party Chairperson and circulation by the EMEA secretariat.

## **10. General Provisions**

The Members of the Efficacy Working Party as well as observers and all experts shall be bound, even after the cessation of their duties, not to disclose any information, which, by its nature, must be covered by individual professional secrecy.

When participating in international or other fora on behalf of the CHMP, members shall ensure, the views expressed are those of the CHMP.

When participating in international or other fora not specifically on behalf of the CHMP, members shall make clear that the views expressed are their own views and not necessarily those of the CHMP.